17 unknown. 17 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Unknown 17 |
| Phase 2 | 10 | Unknown 10 |
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| A Study of FCN-338 in Patients With Chronic CLL/SLL FCN-338 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Unknown | Fochon Pharmaceuticals, Ltd. | 99 | 2021-05-13 | 2024-08-13 |
| Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients Kineret - Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Dr. David Spaner | 12 | 2021-05-01 | 2021-03-19 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2021-04-10 | 2021-04-08 |
| Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors hCD19.IL15.CAR-iNKT - Acute Lymphoblastic Leukemia, B-cell Lymphoma | Phase 1 | Unknown | Kai Lin Xu; Jun Nian Zheng | 20 | 2021-03-19 | 2021-03-29 |
| A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma LP-108 tablet - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 74 | 2020-05-01 | 2023-05-01 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Drugs and anti-CD19 CAR transduced T cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 100 | 2017-06-30 | 2017-06-20 |
| Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia CT-1530 - Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Centaurus Biopharma Co., Ltd. | 200 | 2017-04-01 | 2017-07-19 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects TL-895, Navtemadlin - Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Telios Pharma, Inc. | 130 | 2016-08-26 | 2023-07-13 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Fludarabine, Cyclophosphamide, Anti-CD19-CAR transduced T cells - Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shenzhen Second People's Hospital | 36 | 2015-04-01 | 2016-08-03 |
| Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) valproic acid and 2-chlorodeoxyadenosine - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 33 | 2010-12-01 | 2012-06-07 |
| The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Milatuzumab - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Kaplan Medical Center | 15 | 2009-04-01 | 2010-06-02 |
| Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia AQ4N (Chemotherapy) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Novacea | 55 | 2005-03-01 | 2007-05-07 |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia Iodine-131 Anti-B1 Antibody - Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Corixa Corporation | 30 | 1999-07-01 | 2005-06-24 |
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Mantle-Cell (4) · Leukemia, Prolymphocytic, B-Cell (3) · Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (1)
Chronic Disease (17) · Disease Attributes (17) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Leukemia (17) · Leukemia, B-Cell (17) · Leukemia, Lymphoid (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · Cyclophosphamide (2) · Immunotherapy, Adoptive (2) · fludarabine (2) · AQ4N (1) · Cladribine (1) · Drug Therapy (1) · Interleukin 1 Receptor Antagonist Protein (1) · Pharmaceutical Preparations (1) · Valproic Acid (1) · milatuzumab (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · tositumomab I-131 (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Centaurus Biopharma Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Corixa Corporation (1) · Dr. David Spaner (1) · Fochon Pharmaceuticals, Ltd. (1) · Kai Lin Xu; Jun Nian Zheng (1) · Kaplan Medical Center (1) · Novacea (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shenzhen Second People's Hospital (1) · Telios Pharma, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (11) · United States (3) · Belgium (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
David Spaner, MD (1) · Eric Van Den Neste, MD, PhD (1) · Huang Hui Qiang, MD (1) · Junnian Zheng, Ph.D (1) · Kailin Xu, Ph.d (1) · Lin Yang, Ph.D. (1) · Michal Haran, MD (1) · Mingjun Wang, MD (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1) · Ying Feng, MD (1) · Yu Hu (1) · Yuankai Shi, M.D. (1)
PMID 28054442, PMID 34515338, PMID 35126471, PMID 39121163
2016 (1)